ALPMY

Astellas Pharma Inc. [ALPMY] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

ALPMY Stock Summary

Top 10 Correlated ETFs

ALPMY


Top 10 Correlated Stocks

ALPMY


In the News

07:01 28 Mar 2024 ALPMY

US FDA declines to approve Astellas' gastric cancer drug

Japan's Astellas Pharma said on Monday the U.S. Food and Drug Administration (FDA) has declined to approve its experimental drug to treat a type of gastric cancer, citing issues related to a third-party manufacturer.

07:39 28 Mar 2024 ALPMY

Astellas gets green light from European Commission for menopause drug

The European Commission has approved Astellas Pharma's fezolinetant, a non-hormonal treatment for managing moderate-to-severe vasomotor symptoms (VMS) like hot flashes and night sweats in menopausal women. This approval addresses a large unmet need, as up to 97% of women aged 40 to 64 in Europe experience these symptoms.

12:06 28 Mar 2024 ALPMY

Astellas Pharma Inc. (ALPMF) Q2 2023 Earnings Call Transcript

Astellas Pharma Inc. (OTCPK:ALPMF) Q2 2023 Earnings Conference Call November 1, 2023 3:00 AM ET Company Participants Hiromitsu Ikeda - Corporate Head, Advocacy & Relations Atsushi Kitamura - Chief Financial Officer Naoki Okamura - Representative Director, President & Chief Executive Officer Yoshitsugu Shitaka - Chief Scientific Officer Tadaaki Taniguchi - Chief Medical Officer Claus Zieler - Chief Commercial Officer Conference Call Participants Hidemaru Yamaguchi - Citigroup Securities Kazuaki Hashiguchi - Daiwa Securities Shinichiro Muraoka - Morgan Stanley MUFJ Securities Seiji Wakao - JPMorgan Securities Akinori Ueda - Goldman Sachs Securities Shinya Tsuzuki - Mizuho Securities Hiromitsu Ikeda Thank you very much for joining Astellas Pharma Inc.'s FY 2023 Second Quarter Financial Results Announcement meeting out of a very busy schedule. I'm delighted to serve us as moderator today.

09:01 28 Mar 2024 ALPMY

New Strong Sell Stocks for October 2nd

ALPMY, BTDPY and ALRS have been added to the Zacks Rank #5 (Strong Sell) List on October 2, 2023.

07:31 28 Mar 2024 ALPMY

New Strong Sell Stocks for September 26th

ALPMY, ASH and DHC have been added to the Zacks Rank #5 (Strong Sell) List on September 26, 2023.

08:17 28 Mar 2024 ALPMY

New Strong Sell Stocks for September18th

ALPMY, CBRE and FMAO have been added to the Zacks Rank #5 (Strong Sell) List on September 18, 2023.

02:19 28 Mar 2024 ALPMY

Astellas withdraws lawsuit challenging Medicare drug price negotiation plans

Japan-based Astellas Pharma on Wednesday withdrew a lawsuit filed against the U.S. government, days after its prostate cancer drug was spared from the first list of drugs that will be subject to Medicare price negotiations.

07:01 28 Mar 2024 ALPMY

How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?

Major pharmaceutical companies including Johnson & Johnson NYSE: JNJ, Novartis AG NYSE: NVS, Bristol-Myers Squibb (NYSE: BMY), Merck & Co., Inc. NYSE: MRK, Eli Lilly & Co. NYSE: LLY and Amgen Inc. NASDAQ: AMGN were trading normally following news that their drugs would be subject to next year's Medicare price negotiations.

09:01 28 Mar 2024 ALPMY

New Strong Sell Stocks for August 21st

ALPMY, CYRX and DRCT have been added to the Zacks Rank #5 (Strong Sell) List on August 21, 2023.

10:42 28 Mar 2024 ALPMY

Astellas Pharma Inc. (ALPMF) Q2 2023 Earnings Call Transcript

Astellas Pharma Inc. (OTCPK:ALPMF) Q2 2023 Earnings Conference Call August 1, 2023 4:00 AM ET Company Participants Hiromitsu Ikeda - Corporate Head, Advocacy and Relations Naoki Okamura - Representative Director, President and CEO Yoshitsugu Shitaka - Chief Scientific Officer Tadaaki Taniguchi - Chief Medical Officer Claus Zieler - Chief Commercial Officer Conference Call Participants Hidemaru Yamaguchi - Citigroup Securities Kazuaki Hashiguchi - Daiwa Securities Naomi Kumagai - Mitsubishi UFJ Morgan Stanley Securities Akinori Ueda - Goldman Sachs Securities Shinichiro Muraoka - Morgan Stanley MUFJ Securities Madoka Sato - Schroder Investment Management Kasumi Haruta - Credit Suisse Securities Shinya Tsuzuki - Mizuho Securities Hiromitsu Ikeda Thank you very much for your participation on this earning call for Q1 FY 2023 Financial Results Ended June 30, 2023. I am Ikeda, Head of Corporate Communications, serving as the moderator for today.

ALPMY Financial details

Company Rating
Strong Buy
Market Cap
19.76B
Income
58M
Revenue
1543.32B
Book val./share
837.96
Cash/share
159.11
Dividend
-
Dividend %
-
Employees
14.48K
Optionable
No
Shortable
Yes
Earnings
24 Apr 2024
P/E
92.54
Forward P/E
0.13
PEG
-9.29
P/S
2.05
P/B
1.92
P/C
0.07
P/FCF
22.2
Quick Ratio
0.75
Current Ratio
0.96
Debt / Equity
0.58
LT Debt / Equity
0.31
-
-
EPS (TTM)
0.25
EPS next Y
81.43
EPS next Q
5.23
EPS this Y
-19.14%
EPS next Y
32471.26%
EPS next 5Y
73251.7%
EPS last 5Y
-13.96%
Revenue last 5Y
3.06%
Revenue Q/Q
7.6%
EPS Q/Q
-1098.77%
-
-
-
-
SMA20
-0.82%
SMA50
-9.44%
SMA100
-13.59%
Inst Own
0%
Inst Trans
0%
ROA
1%
ROE
2%
ROC
0.03%
Gross Margin
82%
Oper. Margin
4%
Profit Margin
2%
Payout
320%
Shs Outstand
1.79B
Shs Float
1.79B
-
-
-
-
Target Price
-
52W Range
10.29-16.91
52W High
-31.63%
52W Low
+9.4%
RSI
49.04
Rel Volume
0.9
Avg Volume
249.1K
Volume
224.87K
Perf Week
0.83%
Perf Month
0.46%
Perf Quarter
-19.02%
Perf Half Y
-24.16%
-
-
-
-
Beta
0.283
-
-
Volatility
0.07%, 0.14%
Prev Close
-1.08%
Price
10.94
Change
2.05%

ALPMY Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-03-31

Metric History 2019-03-312020-03-312021-03-312022-03-31 2023-03-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
676.2693.34672.83700.74834.4
Net income per share
115.05104.1564.9367.0854.24
Operating cash flow per share
135.32119.42165.78139.57182.59
Free cash flow per share
108.3477.91124.0898.24133.95
Cash per share
162.37174.74178.6182.34217.92
Book value per share
651.38687.12746.38789.48828.54
Tangible book value per share
312.04152.51242.67288.61339.03
Share holders equity per share
651.38687.12746.38789.48828.54
Interest debt per share
1.71186.68117.6288.3178.11
Market cap
3286.75B3064.02B3171.06B3531.45B3441.27B
Enterprise value
2976.88B3158.96B3123.19B3428.21B3264.44B
P/E ratio
14.7915.6826.328.4634.86
Price to sales ratio
2.522.362.542.722.27
POCF ratio
12.5713.6710.313.6810.36
PFCF ratio
15.720.9613.7619.4314.12
P/B Ratio
2.612.382.292.422.28
PTB ratio
2.612.382.292.422.28
EV to sales
2.282.432.52.642.15
Enterprise value over EBITDA
8.669.139.6511.448.35
EV to operating cash flow
11.3914.110.1413.289.82
EV to free cash flow
14.2221.6113.5518.8713.39
Earnings yield
0.070.060.040.040.03
Free cash flow yield
0.060.050.070.050.07
Debt to equity
00.270.160.110.09
Debt to assets
00.150.10.070.06
Net debt to EBITDA
-0.90.27-0.15-0.34-0.45
Current ratio
1.721.091.471.341.45
Interest coverage
215.1693.02107.4544.4678.85
Income quality
1.181.152.552.083.37
Dividend Yield
0.020.020.020.020.03
Payout ratio
0.320.380.630.691.02
Sales general and administrative to revenue
00.380.40.420.42
Research and developement to revenue
0.160.170.180.190.18
Intangibles to total assets
0.350.430.410.40.36
Capex to operating cash flow
-0.2-0.35-0.25-0.3-0.27
Capex to revenue
-0.04-0.06-0.06-0.06-0.06
Capex to depreciation
-0.82-1.17-1.07-0.96-0.84
Stock based compensation to revenue
00000
Graham number
1.3K1.27K1.04K1.09K1.01K
ROIC
0.20.130.130.10.12
Return on tangible assets
0.180.150.090.090.06
Graham Net
11.51-183.72-110.88-83.94-71.66
Working capital
359.49B68.81B280.22B235.94B323.92B
Tangible asset value
602.83B286.14B450.68B533.85B617.05B
Net current asset value
217.91B-158.49B-14.93B51.27B101.39B
Invested capital
00.270.160.110.09
Average receivables
345.33B366.67B363.88B380.58B424.89B
Average payables
163.09B178.62B148.37B127.76B135.49B
Average inventory
149.57B151.26B157.55B158.58B163.73B
Days sales outstanding
101.35103.99104.33113.77107.14
Days payables outstanding
206.65210.68168.79169.64156.63
Days of inventory on hand
168.98185.03221.95198.62194.78
Receivables turnover
3.63.513.53.213.41
Payables turnover
1.771.732.162.152.33
Inventory turnover
2.161.971.641.841.87
ROE
0.180.150.090.080.07
Capex per share
-26.98-41.51-41.7-41.33-48.65

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q3

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
220.68195.77209218.73235.2
Net income per share
26.56-25.4918.46-0.818.09
Operating cash flow per share
40.2665.257.5922.3529.59
Free cash flow per share
28.8949.71-1.535.121.08
Cash per share
226.78219.19335.98202.83159.11
Book value per share
861.7833.34879.73914.38837.96
Tangible book value per share
345.58341352.42-165.67-187.89
Share holders equity per share
861.7833.34879.73914.38837.96
Interest debt per share
3.9477.71201.6497.46487.09
Market cap
3608.51B3421.44B3862.73B3721.01B3009.03B
Enterprise value
3375.43B3244.61B3660.24B4377.44B3725.7B
P/E ratio
18.64-18.5429.15-637.651.83
Price to sales ratio
8.979.6610.39.497.13
POCF ratio
49.1828.98283.7392.8456.69
PFCF ratio
68.5438.04-1.41K407.1679.59
P/B Ratio
2.32.272.452.272
PTB ratio
2.32.272.452.272
EV to sales
8.399.169.7611.168.83
Enterprise value over EBITDA
30.2342.4941.8658.0542.98
EV to operating cash flow
4627.48268.86109.2270.19
EV to free cash flow
64.1236.07-1.33K478.9898.54
Earnings yield
0.01-0.010.0100
Free cash flow yield
0.010.03000.01
Debt to equity
00.090.230.540.58
Debt to assets
00.060.130.250.26
Net debt to EBITDA
-2.09-2.32-2.328.718.27
Current ratio
1.521.451.330.960.91
Interest coverage
31.6325.7423.616.0614.03
Income quality
1.52-2.560.41-27.473.66
Dividend Yield
0.0200.0100.02
Payout ratio
1.1301.6304.32
Sales general and administrative to revenue
0.410.450.450.460.47
Research and developement to revenue
0.170.20.170.20.18
Intangibles to total assets
0.370.360.340.550.55
Capex to operating cash flow
-0.28-0.24-1.2-0.77-0.29
Capex to revenue
-0.05-0.08-0.04-0.08-0.04
Capex to depreciation
-0.9-1.22-0.7-0.79-0.33
Stock based compensation to revenue
00000
Graham number
717.6691.33604.55129.39390.55
ROIC
0.040.030.0200.01
Return on tangible assets
0.03-0.030.0200.01
Graham Net
-55.64-72.07-88.45-588.31-606.25
Working capital
366.69B323.92B325.96B-45.5B-103.61B
Tangible asset value
629.82B617.05B632.31B-297.03B-337.06B
Net current asset value
129.07B101.39B97.91B-786.92B-815.33B
Invested capital
00.090.230.540.58
Average receivables
463.23B454.36B461.5B490.91B505.25B
Average payables
140.38B137.24B139.34B142.84B148.84B
Average inventory
165.93B168.8B187.31B206.94B219.81B
Days sales outstanding
103.6113.25114.53115.81107.91
Days payables outstanding
144.46176.42159.71133.76124.97
Days of inventory on hand
175.66219.38230.98194.08187.73
Receivables turnover
0.870.790.790.780.83
Payables turnover
0.620.510.560.670.72
Inventory turnover
0.510.410.390.460.48
ROE
0.03-0.030.0200.01
Capex per share
-11.38-15.54-9.12-17.26-8.51

ALPMY Frequently Asked Questions

What is Astellas Pharma Inc. stock symbol ?

Astellas Pharma Inc. is a JP stock and trading under the symbol ALPMY

What is Astellas Pharma Inc. stock quote today ?

Astellas Pharma Inc. stock price is $10.94 today.

Is Astellas Pharma Inc. stock public?

Yes, Astellas Pharma Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap